January 26, 2012
With a history of more than 20 years, KBNP, INC. has positioned itself as a reputable leader in the animal health field with an on-going passion to develop new medicines. Bae Yoon-Young, export manager of KBNP, discusses how the Korean-based company keeps pace with the opportunities for advances in animal health.
How has KBNP developed over the years?
KBNP was established in 1988 by a group of young people, who had great ambitions to produce world-class animal health products, and ever since the company has focussed on the path for the prevention and treatment of animal diseases.
For the past two decades, the KBNP, has made ceaseless efforts to develop new medicine and open new overseas markets on the basis of the company motto of "Living Together! Growing Together!"
First, we have produced a wide range of animal health products. We produce high quality vaccines for poultry, pig, cattle, canine, and aquaculture. Furthermore, we produce various types of pharmaceuticals including injectables, oral solutions, disinfectants, feed additives, and water soluble powder. With this range of products, it helps the business to be more responsive to customer needs from various countries.
Third, KBNP has retained fine talent and strive to secure an outstanding work force.
Finally, we have a few patents for manufacturing technique for vaccine and pharmaceuticals. It contributes to the manufacture of high quality products and improving product differentiation.
How does KBNP fare particularly in Asia?
KBNP is solidifying its position as a leader in the animal health field through relentless research and development of new products, product differentiation, and investment in facilities in order to meet international standards.
How does KBNP market its products in Asia?
Participating in international exhibitions, expos, and forum gives us good exposure and on top of that, we advertise our main products with famous magazines.
KBNP focuses on continuous R&D and also marketing strategies to make sure that they cater to the different needs of different markets in each country appropriately.
What are the most pressing diseases faced by Asia's livestock sector?
In Asia's poultry market, pressing diseases include Newcastle Disease (ND), Infectious Bronchitis and Infectious Bursal Disease. Those diseases have inflicted huge economic losses to the poultry industry.
Conventional ND vaccines face limitations to prevent present wild Newcastle Disease Virus (Genotype VII), and this is directly reflected in the huge economic losses in poultry industries.
How does KBNP contribute in addressing these challenges?
KBNP launched a new vaccine for prevention of important infectious diseases caused by present wild virus. Dalguban N+ is the ND vaccine brand name of KBNP. The vaccine can protect from the ND problem with genotype I, II & VII, and minimise the virus shedding due to having homologous antigenicity with the wild virus strain.
Besides, we develop and launch the market-matched products with the recommended medication programme by surveying the international disease situation continuously.
KBNP manufactures various types of animal health products. Which product class has grown most quickly?
Our main product class is vaccine and it has grown at an impressive pace although the registration is very strict and takes a long time to be completed.
Which product class do you expect to grow most quickly in the future?
As Dalguban N+ will be launching in some countries, we expect that our vaccines will grow quickly in future.
Where would you see new opportunities for advances in animal health?
Now, people focus on the prevention of disease through biosecurity rather than the treatment approach. Also, bacteria resistance to antibiotics and public health matters are emerging as a major issue lately. Thus, our company is striving to keep pace with this flow in the market. We develop and launch the prophylactic programme based on each country and customer needs with our high quality product line.
How is product development changing at KBNP?
We have continuously devoted to research and development for new techniques in product manufacturing. Our efforts in product manufacturing, especially in poultry vaccines, have resulted in registering local and international patents.
Dalguban N+ vaccine brand group and Dalguban B+ live vaccine are representative products manufactured with high technology. Those vaccines are more advanced and more homologous.
How have bans on AGPs in the EU, Korea and elsewhere impacted animal health?
As more and more countries ban AGPs, many companies concentrate on development of substitutes of AGPs. However, there are not yet complete products available to substitute AGPs perfectly. Due to ban on AGPs, we think the livestock industry should focus on biosecurity more than before by vaccination.
Do you expect more Asian countries to move towards the direction of banning AGPs? Why is that so?
Yes, many people in the livestock industry expect that more Asian countries will move towards the direction of banning AGPs. Actually, AGPs are used for improvement of productivity in livestock industry by controlling bacterial infection. However, antibiotic resistance in humans and animals is a growing public health concern worldwide. When a person or animal is infected with an antibiotic-resistant bacterium, treatment becomes more difficult because standard antibiotic therapies become less effective or may not work at all. Therefore, the development of substitute of AGPs has become more urgent.
What other key trends do you foresee in Asia's animal health industry?
Globalisation has caused the diseases to spread at a faster pace. This tendency is especially evident in Asia. Thus, customers need products that match their current market situation. This also means that the products developed in Asia are more effective for the Asian market compared to the products developed in the EU or the US.